Success Metrics

Clinical Success Rate
82.4%

Based on 14 completed trials

Completion Rate
82%(14/17)
Active Trials
0(0%)
Results Posted
50%(7 trials)
Terminated
3(14%)

Phase Distribution

Ph phase_4
7
32%
Ph phase_2
4
18%
Ph phase_3
9
41%
Ph not_applicable
1
5%
Ph early_phase_1
1
5%

Phase Distribution

1

Early Stage

4

Mid Stage

16

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 2Efficacy & side effects
4(18.2%)
Phase 3Large-scale testing
9(40.9%)
Phase 4Post-market surveillance
7(31.8%)
N/ANon-phased studies
1(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

14 of 21 finished

Non-Completion Rate

33.3%

7 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Active(1)
Completed(14)
Terminated(7)

Detailed Status

Completed14
Withdrawn4
Terminated3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
82.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 24 (18.2%)
Phase 39 (40.9%)
Phase 47 (31.8%)
N/A1 (4.5%)

Trials by Status

withdrawn418%
not_yet_recruiting15%
completed1464%
terminated314%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT01938547Phase 4

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

Terminated
NCT05175547Phase 3

Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Completed
NCT06063772Phase 4

Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia

Not Yet Recruiting
NCT02011321Phase 2

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

Withdrawn
NCT03719001Early Phase 1

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

Completed
NCT01369147Phase 2

The Energy Dose Study

Terminated
NCT03300479Phase 4

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Withdrawn
NCT01033370Phase 4

A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)

Terminated
NCT01645111Phase 2

An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion

Completed
NCT00952081Phase 4

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

Completed
NCT00799604Phase 2

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

Completed
NCT00803634Phase 3

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

Completed
NCT00666328Phase 3

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

Completed
NCT00093249Phase 3

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Completed
NCT00369837Phase 3

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Completed
NCT00093262Phase 3

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Completed
NCT00093912Phase 3

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

Completed
NCT00093925Phase 3

Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)

Completed
NCT00093886Phase 3

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Completed
NCT01910532Phase 4

The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
22